This study is looking at two products, uridine and pravastatin, to see if they can help with lipoatrophy (the loss of fat from cheeks, limbs and buttocks). Over 28 weeks, the study will compare people who are being treated with one, both or neither of the products to see if there are any changes. The study will also monitor any side effects to see whether the products are safe.
This is the Phase III study of raltegravir - from the new drug class of integrase inhibitors which are designed to attack HIV in a different way to the other classes currently available on the Australian market.
The study compares an optimised background therapy used with and without raltegravir. Comparing results will allow the researchers to look at whether the addition of an integrase inhibitor is more effective against HIV than using the current drugs alone.
This trial is providing access to an experimental non-nucleoside (NNRTI) called etravirine for people who did not reach undetectable viral load levels on either of the prior DUET studies.
The study will look at the long-term safety and tolerability of etravirine as part of an optimised background regimen including darunavir and other drugs chosen by their doctor.
All people will receive etravirine until the drug is approved and commercially available.
This was a rollover study, to provide darunavir for people who participated in one of two previous clinical trials before it was approved.
Etravirine (TMC 125) is an experimental non-nucleoside reverse transcriptase inhibitor (NNRTI). This trial is to study the safety and tolerability of this treatment, and its effectiveness against HIV.
The trial is randomised and people take either etravirine in combination with an optimized background regimen or a combination without etravirine.
This is an extension study of a Phase II trial for a new treatment called apricitabine. It is basically a study which allows ongoing access to this treatment for people who were involved in the Phase II study.
This is an ongoing Phase III trial of an HIV antiretroviral from a new class of drugs, known as 'entry inhibitors'. Entry inhibitors work by trying to prevent HIV from attaching to or being able to enter and infect cells.
This is an ongoing trial of an experimental HIV antiviral from a new class of drugs, known as 'entry inhibitors'. Entry inhibitors work by trying to prevent HIV from attaching to or being able to enter and infect cells.
The drug in this trial, maraviroc, is called a CCR5 inhibitor, and is designed to prevent HIV from attaching to specific 'receptors' on the surface of human immune cells. If HIV can't attach to the cell, it can't infect it (see Background Info for more discussion). The particular cell 'marker' which HIV uses to attach to a cell is called CCR5.
The purpose of this study is to measure how well HIV is controlled in the blood of patients taking a regimen including raltegravir - a drug from the new class of integrase inhibitors.
This is a trial for a new antiretroviral called apricitabine - an experimental nucleoside reverse transcriptase inhibitor for people who are resistant to other NRTIs, and who have the M184V mutation.
This study will look at how safe, easy to take and effective apricitabine is in people who are resistant to 3TC. If successful, it is hoped to use it as an alternative.
This information was retrieved from the Treataware website (www.treataware.info) on 21 Nov 2008. For further information, please consult the website or call the NAPWA office on 02 8568 0300.